Dr. Reddy's Laboratories Ltd.

Financial

	Dr. Reddy's Lab	Torrent Pharma	Cipla
Operational Metrics
Pharmaceutical Sector
Number of ANDA's Filed in USA	361.0 .	168.0 .	284.0 .
Number of ANDA's Approved By USFDA	288.0 .	132.0 .	211.0 .
Domestic Sales Growth - YoY	11.1 %	14.1 %	11.6 %
Global DMFs filed	1251.0 .	n/a	n/a
R&D as a % of Total Sales	8.5 %	5.1 %	6.3 %
Financials
5 yr Average ROE	14.9 %	20.0 %	12.48 %
5yr average Equity Multiplier	1.41	2.34	1.31
5yr Average Asset Turnover Ratio	0.77	0.65	0.78
5yr Avg Net Profit Margin	14.03 %	13.21 %	12.29 %
Price to Book	3.28	14.5	3.89
P/E	19.46	57.6	23.03
5yr Avg Cash Conversion Cycle	64.1 Days	-189.03 Days	-4.58 Days
Inventory Days	75.39 Days	54.5 Days	58.34 Days
Days Receivable	99.54 Days	41.38 Days	45.49 Days
Days Payable	102.35 Days	318.84 Days	110.05 Days
5yr Average Interest Coverage Ratio	34.06	5.79	33.93
5yr Avg ROCE	19.83 %	23.72 %	17.45 %
5yr Avg Operating Profit Margin	21.19 %	29.52 %	21.56 %
5 yr average Debt to Equity	0.12	0.83	0.07
5yr CAGR Net Profit	22.45 %	10.08 %	21.66 %
5yr Average Return on Assets	10.71 %	8.58 %	9.64 %
Shareholdings
Promoter Holding	26.64 %	68.31 %	29.2 %
Share Pledged by Promoters	0.0	0.0	0.0
Change in Promoter Holding (3 Yrs)	-0.08 %	-2.94 %	-4.43 %
Change in Mutual Fund Holding (3 Yrs)	-1.23 %	-2.45 %	6.6 %

Business

	Dr. Reddy's Lab	Torrent Pharma	Cipla
Product Wise Break-Up	Product Wise Break-Up Formulations 86.31 Pharmaceutical 13.52 Proprietary 0.17 US Formulations 0 Domestic formulations 0 Contract Manf. 0 Brazil/Latam 0 Germany/Europe 0 New ventures 0 Pharmaceuticals 0	Product Wise Break-Up Domestic Formulations 42.15 Proprietary 0 Brazil 8.98 Germany 13.15 Formulations 0 Contract Manufacturing 6.15 New ventures 0 Pharmaceuticals 0 US Formulations 20.71 Pharmaceutical 0 Others 8.86	Product Wise Break-Up Domestic formulations 0 Proprietary 0 Brazil/Latam 0 Germany/Europe 0 Formulations 0 Contract Manf. 0 New ventures 4.25 Pharmaceutical 95.75 US Formulations 0 Pharmaceutical 0
Location Wise Break-Up	Location Wise Break-Up USA 48.56 India 17.36 Russia 7.99 Germany 0 Brazil 0 SAGA 0 Europe 0 Global API 0 Rest of the World 0 Emerging Markets 0 North America 0 Others 26.09	Location Wise Break-Up Russia 0 Germany 9.67 Emerging Markets 0 North America 0 Rest of the World 0 Europe 0 Brazil 11.86 SAGA 0 India 52.21 USA 10.21 Global API 0 Others 16.05	Location Wise Break-Up Russia 0 Germany 0 Emerging Markets 0 North America 29.0 Rest of the World 0 Europe 12.0 Brazil 0 SAGA 14.0 India 42.0 USA 0 Global API 2.0 Others 1.0
Operating Profit Break-Up	Operating Profit Break-Up Global Generics 94.57 Pharmaceutical Services and Active Ingredients 5.34 Proprietary Products 0.08 New Ventures 0 Pharmaceuticals 0 Others 0.01	-	Operating Profit Break-Up New Ventures 0 0 Global Generics 0 Pharmaceuticals 100.0 Proprietary Products 0
Therapeutic Area Break-Up	Therapeutic Area Break-Up Oncology 27.53 Central Nervous System (CNS) 12.12 Pain Management 9.77 Gastro Intestinal 9.52 Respiratory 7.04 Cardiac Science 6.65 Anti-Infective 6.48 Gynae 0 Anti-infective 0 Pain 0 Anti- diabetic 0 CNS 0 Gastro-intestinal 0 Cardiac 0 Rest 0 VMN 0 Others 20.89	Therapeutic Area Break-Up Oncology 0 Central Nervous System (CNS) 0 Pain Management 0 Cardiac Science 0 Gastro Intestinal 17.0 Anti-Infective 3.0 Rest 2.0 VMN 12.0 Cardiac Science 26.0 Gastro Intestinal 0 Anti - Diabetes 9.0 CNS 15.0 Anti-Infective 0 Pain Management 7.0 Gynecology 2.0 Respiratory 0 Others 7.0	-
Asset Break-Up	Asset Break-Up India 80.24 Switzerland 8.45 USA 2.37 South Africa 0 USA 0 Others 8.94	Asset Break-Up Switzerland 0 India 96.58 USA 0.32 South Africa 0 Others 3.1	Asset Break-Up Switzerland 0 India 46.99 USA 30.03 South Africa 18.71 Others 4.27

Dr. Reddy's Laboratories Ltd.

Dr. Reddy's Laboratories Ltd.

SIGN UP FOR FREE